Design of Carborane-Based Hypoxia-Inducible Factor Inhibitors

Guangzhe Li, H. Ban, Hiroyuki Nakamura
{"title":"Design of Carborane-Based Hypoxia-Inducible Factor Inhibitors","authors":"Guangzhe Li, H. Ban, Hiroyuki Nakamura","doi":"10.1002/9781119275602.CH1.3","DOIUrl":null,"url":null,"abstract":"Cancer is a disease involving uncontrolled cell growth. In a solid tumor, cancer cells are deprived of oxygen due to their rapid growth. As a result, the oxygen concentration of the tumor regions distant from blood vessels is significantly lower than that of healthy tissues, causing hypoxia in tumor. Tumor hypoxia upregulates a number of genes involved in tumor angiogenesis, cellular energy metabolism, metastasis, cell prolifera‐ tion, and resistance to apoptosis. Hypoxia‐inducible factor (HIF) is a transcriptional factor that plays an important role as an oxygen sensor in cells. HIF is a heterodimer composed of α subunits (HIF1α, ‐2α, and ‐3α) and a β subunit (HIF1β, which is also known as an aryl hydrocarbon receptor nuclear translocator [ARNT]) [1,2]. Under aerobic conditions, posttranslational hydroxylation of proline residues in HIF1α by prolyl hydroxylase (PHD) induces ubiquitination by the von Hippel–Lindau (VHL) tumor suppressor protein, a component of the E3 ubiquitin ligase complex, resulting in the oxygen‐dependent degradation through a ubiquitin– proteasome pathway. Under hypoxic conditions, HIF1α does not undergo the oxygen‐dependent degradation due to the inactivation of PHD; instead, it translocates into the nucleus, where it dimerizes with the constitutively expressed HIF1β to form a heterodimeric complex. HIF binds to the hypoxia response element (HRE) DNA sequence with co‐activators to activate various genes, including glucose transporters, glycolytic enzymes, angiogenic growth factors, and several molecules involved in apoptosis and cell proliferation [3,4]. The activated HIF plays pivotal roles in various pathological conditions, including inflammation, cardiovascular disorder, and cancer. Indeed, overexpression of HIF1α has been observed in human cancers, including brain, breast, colon, lung, ovary, and prostate cancers [5]; thus, HIF1α is a novel target of cancer therapy. We have studied a boron‐based medicinal drug design. A boron atom has a vacant orbital and readily interconverts between the neutral sp2 and anionic sp3 hybridization Design of Carborane‐Based Hypoxia‐Inducible Factor Inhibitors Guangzhe Li, Hyun Seung Ban, and Hiroyuki Nakamura","PeriodicalId":124832,"journal":{"name":"Boron-Based Compounds","volume":"2 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Boron-Based Compounds","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/9781119275602.CH1.3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Cancer is a disease involving uncontrolled cell growth. In a solid tumor, cancer cells are deprived of oxygen due to their rapid growth. As a result, the oxygen concentration of the tumor regions distant from blood vessels is significantly lower than that of healthy tissues, causing hypoxia in tumor. Tumor hypoxia upregulates a number of genes involved in tumor angiogenesis, cellular energy metabolism, metastasis, cell prolifera‐ tion, and resistance to apoptosis. Hypoxia‐inducible factor (HIF) is a transcriptional factor that plays an important role as an oxygen sensor in cells. HIF is a heterodimer composed of α subunits (HIF1α, ‐2α, and ‐3α) and a β subunit (HIF1β, which is also known as an aryl hydrocarbon receptor nuclear translocator [ARNT]) [1,2]. Under aerobic conditions, posttranslational hydroxylation of proline residues in HIF1α by prolyl hydroxylase (PHD) induces ubiquitination by the von Hippel–Lindau (VHL) tumor suppressor protein, a component of the E3 ubiquitin ligase complex, resulting in the oxygen‐dependent degradation through a ubiquitin– proteasome pathway. Under hypoxic conditions, HIF1α does not undergo the oxygen‐dependent degradation due to the inactivation of PHD; instead, it translocates into the nucleus, where it dimerizes with the constitutively expressed HIF1β to form a heterodimeric complex. HIF binds to the hypoxia response element (HRE) DNA sequence with co‐activators to activate various genes, including glucose transporters, glycolytic enzymes, angiogenic growth factors, and several molecules involved in apoptosis and cell proliferation [3,4]. The activated HIF plays pivotal roles in various pathological conditions, including inflammation, cardiovascular disorder, and cancer. Indeed, overexpression of HIF1α has been observed in human cancers, including brain, breast, colon, lung, ovary, and prostate cancers [5]; thus, HIF1α is a novel target of cancer therapy. We have studied a boron‐based medicinal drug design. A boron atom has a vacant orbital and readily interconverts between the neutral sp2 and anionic sp3 hybridization Design of Carborane‐Based Hypoxia‐Inducible Factor Inhibitors Guangzhe Li, Hyun Seung Ban, and Hiroyuki Nakamura
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
碳硼烷类缺氧诱导因子抑制剂的设计
癌症是一种涉及细胞不受控制生长的疾病。在实体瘤中,癌细胞由于快速生长而缺氧。因此,远离血管的肿瘤区域的氧浓度明显低于健康组织,导致肿瘤缺氧。肿瘤缺氧可上调一些与肿瘤血管生成、细胞能量代谢、转移、细胞增殖和细胞凋亡抵抗有关的基因。缺氧诱导因子(Hypoxia - inducible factor, HIF)是一种转录因子,在细胞中作为氧传感器起着重要的作用。HIF是一种异源二聚体,由α亚基(HIF1α、‐2α和‐3α)和β亚基(HIF1β,也被称为芳烃受体核转运子[ARNT])组成[1,2]。在有氧条件下,脯氨酸羟化酶(prolyl hydroxylase, PHD)对HIF1α中脯氨酸残基的翻译后羟基化诱导von Hippel-Lindau (VHL)肿瘤抑制蛋白(E3泛素连接酶复合物的一个组成部分)的泛素化,通过泛素-蛋白酶体途径导致氧依赖性降解。在缺氧条件下,HIF1α由于PHD失活而不经历氧依赖性降解;相反,它易位到细胞核中,在那里它与组成性表达的HIF1β二聚体形成异二聚体复合物。HIF通过共激活因子与缺氧反应元件(HRE) DNA序列结合,激活多种基因,包括葡萄糖转运蛋白、糖酵解酶、血管生成生长因子和一些参与细胞凋亡和细胞增殖的分子[3,4]。激活的HIF在各种病理条件中起着关键作用,包括炎症、心血管疾病和癌症。事实上,hif α在人类癌症中已被观察到过表达,包括脑癌、乳腺癌、结肠癌、肺癌、卵巢癌和前列腺癌[5];因此,HIF1α是癌症治疗的新靶点。我们研究了一种硼基药物设计。碳硼烷基缺氧诱导因子抑制剂的设计李光哲,Hyun Seung Ban, Hiroyuki Nakamura
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Nanostructured Boron Compounds for Boron Neutron Capture Therapy (BNCT) in Cancer Treatment Index Half- and Mixed-Sandwich Transition Metal Dicarbollides andnido-Carboranes(-1) for Medicinal Applications Boron Compounds in Molecular Imaging Optimizing the Therapeutic Efficacy of Boron Neutron Capture Therapy (BNCT) for Different Pathologies
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1